Itron heads into its third-quarter report with an awkward contradiction. Management spent the last call arguing that the company's earnings power has structurally stepped up, backed by a record gross margin and a raised full-year outlook. Yet the stock has slid about 9.5% since then, trailing the S&P 500 by nearly 13 percentage points, and now trades just above its post-earnings low. The September quarter is where the margin story has to be joined by something the company has not delivered lately: top-line growth.
Illinois Tool Works delivered the most profitable quarter in its history last time out, raised its full-year outlook for the second time this year, and then watched its stock fall almost 9% while the S&P 500 gained more than 3%. That disconnect sets up the third-quarter report, due before the open on October 27, as a test of whether the company's sudden growth acceleration is durable or a one-quarter burst that the market has already started to discount.
Invesco heads into its third-quarter report with a curious disconnect. Last quarter brought record flows, a jump in operating margin, and a management team confident enough to raise its profitability ambitions. Yet the stock has slipped 5.6% since then while the S&P 500 gained 3.3%, a gap of nearly nine percentage points. The October 27 report, due before the open, has to show whether the market's skepticism is misplaced or whether the second quarter flattered the story.
JetBlue heads into its third-quarter report with an odd contradiction hanging over it. Three months ago, management delivered its most confident call in years: it reinstated full-year guidance, projected double-digit unit revenue gains and introduced a target of at least $1 in earnings per share by 2028. Since then, the stock has fallen nearly 48%, trailing the S&P 500 by more than 51 percentage points and sliding to $2.93, essentially at the bottom of its post-earnings range and far below its 200-day moving average near $5. Either the market sees something the guidance missed, or the report on October 27 has a chance to reset a badly broken narrative.
Johnson Controls heads into its fiscal fourth-quarter report with an unusual problem for a company on a hot streak: Wall Street has already moved past management's own number. After three straight guidance raises, a record backlog and a data-center story that keeps getting bigger, the question is no longer whether demand is there. It is whether the company can convert that demand into profits fast enough to clear a bar that analysts have quietly lifted on its behalf.
Coca-Cola heads into its third-quarter report with an unusual problem for a consumer staples giant: it has been too good at raising the bar. Management has lifted its full-year outlook on three consecutive calls. Volume accelerated to 5% growth last quarter, and trademark Coke posted its best performance in 17 years outside the pandemic period. Now the company has to show that the momentum survives the end of the World Cup glow, tougher year-ago comparisons and a stock trading near its highs.
Coca-Cola FEMSA heads into its third-quarter report with the stock pressing against the top of its post-earnings range and the market clearly leaning bullish. That combination makes this release less about whether the Latin American bottler can grow, which few doubt, and more about whether it can turn top-line growth into the outsized profit gains the Street now expects. Analysts are looking for profit to grow faster than sales, and that gap is where the real test lies.
Lincoln Electric spent most of the past two years telling investors that a recovery in the Americas was coming. Last quarter it finally showed up in the numbers, with volume growing for the first time after nine straight quarters of compression and full-year sales guidance raised for the second time in 2026. The October 27 report, due before the open, is the first chance to see whether that inflection was the start of a durable upturn or a quarter flattered by easy comparisons and timing.
Nautilus Biotechnology heads into its third-quarter report with a stock that has rallied hard since its last update, even though that update delivered the worst scientific news in the company's short public history. Last quarter, management concluded that its flagship broad-scale proteome assay had failed to hit performance targets and withdrew the 2027 launch timeline entirely, pivoting resources toward proteoforms, where customer pull is far stronger. The market has since decided the pivot deserves the benefit of the doubt. The October 27 release, due before the open, is the first real chance to check whether that optimism rests on progress or on hope.
Novartis spent most of the past year telling investors that 2026 would be a tale of two halves, with the generic erosion of Entresto and other older brands front-loaded and growth reappearing later in the year. The second quarter delivered the turn, as sales grew again in constant currency. The third-quarter report, due before the open on October 27, is where that recovery has to show it can hold up without help from the calendar.
Norwood Financial heads into its third-quarter report with its Presence Bank acquisition no longer a project but a profit engine. Last quarter delivered record net income, a net interest margin that jumped to 3.90%, and tangible book value that had already climbed back above its pre-deal level, roughly two years ahead of plan. Management also told investors, in effect, that the easiest part of the margin story is over. This report will show whether Norwood can keep raising earnings once the deposit-cost relief that powered the second quarter stops repeating.
PACCAR heads into its third-quarter report with an odd disconnect. Last quarter, management sounded more confident than it had in a year, with margins widening, profits jumping and a regulatory cloud over 2027 lifting. Yet the stock has fallen 16% since that report, trailing the S&P 500 by more than 19 percentage points. The results due before the open on October 27 are a test of whether the operating story still holds or whether the market spotted cracks that the last call glossed over.
Three months ago Polaris raised its full-year outlook for the second time in 2026 and described itself as operating from a position of strength. The stock market has answered with a shrug and then a shove. Shares have fallen nearly 32% since that report while the S&P 500 gained about 3%, which leaves the third-quarter release, due before the open on October 27, as a referendum on whether the operational improvement management described is durable or was flattered by a one-time tariff refund.
Pentair enters its third-quarter report with a simple promise to keep. Last quarter, management told investors that the pool channel's painful inventory purge would largely run its course by the end of September. This report is the first real chance to check that claim, and with the stock down sharply since July, the market appears to be pricing in the possibility that the destock runs longer or the damage runs deeper.
PayPal heads into its third-quarter report with something it has not had in a while: a raised outlook and a management team that sounded like it was playing offense. The harder question is whether the improving demand signals from last quarter can keep running while operating costs climb faster than revenue. This report lands in the awkward middle of that story, after the guidance raise but before the bulk of the cost savings are supposed to show up.
Royal Caribbean enters its third-quarter report with a split personality. Earnings guidance keeps moving higher, but the pricing engine that powered the cruise recovery has been losing altitude. Last quarter the company raised its full-year profit outlook even as it trimmed its yield expectations. Most of the lift came from its joint ventures, below-the-line items and cost timing, not from charging passengers more. The September quarter is where that tension comes to a head, because it is the period most exposed to the Mediterranean softness management flagged.
Repligen enters its third-quarter report with an unusual setup. Management has raised its full-year outlook twice in a row, and the stock has rewarded that confidence. Yet the company also told investors plainly that this quarter would be the weakest of the year for gross margin. The question on October 27 is whether a quarter that was billed as a mix-driven soft patch arrives on schedule, or whether it shows that the demand recovery behind the stock's run is fragile.
Smithfield Foods told investors last quarter that its third quarter would be the low point of fiscal 2026, and the market has spent the months since pricing in something closer to a worst case. The pork producer heads into its October 27 report before the bell with shares down more than 21% since the last release. The central question is whether the cut to full-year guidance management delivered in the summer was a one-time reset or the first in a series.
Sherwin-Williams heads into its third-quarter report with a peculiar disconnect. Management raised its full-year outlook last quarter for the first time after three straight calls of merely holding the line, yet Wall Street's annual earnings estimate still sits a hair below the bottom of the new range, and the stock has lagged the market since. The report, due before the opening bell on October 27, is the first real test of whether the company's pricing power can absorb a raw material bill that has grown heavier at every turn this year.
Simply Good Foods heads into its fiscal fourth-quarter report with the bad news largely pre-announced and the stock already punished for it. Management has told investors that sales will shrink sharply, that it is deliberately shipping less than consumers are buying, and that a high-single-digit price increase took effect in September. The real question for the October 27 report is whether the new leadership team can show that the shrinking is controlled, and that the pricing move can rebuild margins without driving away shoppers.
SNDL heads into its third-quarter report with an unusual split personality. The core Canadian liquor and cannabis business is shrinking and, last quarter, its production arm barely broke even at the gross line. At the same time, management has opened a path to taking direct control of a scaled U.S. medical cannabis platform that could reshape the company. The October 27 release, due before the open, will show whether the operating slide is stabilizing enough to let that strategic story carry the stock.
SoFi heads into its third-quarter report with a fundamental story that has rarely looked better and a stock that has rarely looked less convinced. Last quarter management called the business a strategic inflection point, raised its full-year revenue outlook for the first time this cycle, and reported record originations, member growth and cross-selling. The market has responded by marking the shares down 6.1% since that report, a 9.3-point lag behind the S&P 500. The October 27 release, due before the open, needs to show that the growth is real and that it can turn into earnings, not just more spending.
S&P Global heads into its third-quarter report with a split personality. Its benchmark franchises, ratings and indices, are running at their fastest pace in years. The slower subscription businesses in energy and market intelligence are struggling to keep up. The October 27 release, due before the opening bell, is the first full quarter without the Mobility division. That makes it the cleanest look yet at whether the leaner company can carry last quarter's momentum.
Three months ago SunCoke Energy finally gave investors what they had been waiting for: a guidance raise. After holding its 2026 consolidated adjusted EBITDA target at $230 million to $250 million through two straight reports, management lifted the range to $250 million to $265 million and raised both operating segments. The third-quarter report is the first chance to see whether that optimism rested on durable improvements, such as a repaired Middletown turbine and Phoenix synergies, or mostly on a terminal surge that management itself called extraordinary.
Three months ago Travel + Leisure did something it had not done all year: it raised its outlook. Full-year adjusted EBITDA guidance moved up to $1.065 billion to $1.085 billion, gross vacation ownership sales guidance climbed to $2.6 billion to $2.675 billion, and management lifted its earnings-per-share growth target to roughly 20% from the teens. The market's response since then has been anything but celebratory. The stock has fallen 13.5% since that report while the S&P 500 gained 2.2%, leaving shares near $64.59, below the 200-day moving average of $70.70 and much closer to the post-earnings low of $60.98 than the $79.49 high. The September-quarter report on October 27, due before the opening bell, is the first real chance to show whether the raise was a durable shift in momentum or a high-water mark.
TransUnion enters its third-quarter report with an odd mix of momentum and caution. Last quarter management raised full-year profit guidance for the second time, credited a sharp rebound in India, and said its core business was running comfortably ahead of plan. It also warned that mortgage activity would weaken in the back half of the year, which leaves its own third-quarter forecast showing a visible slowdown. The question for this report is whether that slowdown turns out to be as narrow and mortgage-specific as management promised, or whether it reaches further into the business.
Three months ago, UPS finally gave investors the quarter they had been promised. The Amazon glide down was finished, U.S. domestic margins had doubled from the first quarter, and management raised full-year guidance for the first time in this cycle. The market's response since then has been a shrug that turned into a slide: the stock has fallen about 10% while the S&P 500 gained roughly 3%. That gap frames the October 27 report. UPS now has to show that the second-quarter inflection was the start of a trend rather than a high-water mark.
Watsco enters its third-quarter report with a story that sounds better than its stock chart. Last quarter management declared that HVAC distribution had returned to more conventional operating conditions, with residential equipment units growing again and July organic sales running up roughly 4% to 5%. The market has not bought it. Shares have fallen about 14% since that call while the S&P 500 gained 3%. The report due before the open on October 27 has to show whether the volume recovery is real enough to outweigh a gross margin that is still resetting lower.
Xylem heads into its third-quarter report with a story that has improved on paper while the stock has gone the other way. Last quarter management raised its full-year profit and margin targets, pointed to surging data center demand and booked the largest orders in company history, yet the shares have fallen 15% since then while the S&P 500 gained more than 3%. That gap frames the question for this report: is the market looking past a slowing top line toward a deeper problem, or is it underpricing a company whose earnings engine is running better than its revenue suggests?
Wave Life Sciences heads into its third-quarter report with a striking disconnect. Last quarter management sounded more confident than it had in some time, pointing to an in-person FDA meeting on an accelerated path for its alpha-1 antitrypsin deficiency drug, WVE-006, and live Phase 2a dosing for its obesity candidate, WVE-007. The stock has since fallen 43.6% while the S&P 500 gained 4.1%. That meeting was slated for the end of summer, so the October 27 release, due before the open, is the first scheduled chance for Wave to tell shareholders what came of it.
Provident Financial Holdings heads into its September-quarter report with an unusual setup: the Street expects earnings to climb sharply from a year ago, yet the California thrift's balance sheet has been growing slowly at best. That puts the burden of proof squarely on net interest margin and expense discipline. If profit growth is going to come without loan growth, it has to come from squeezing more out of every dollar the bank already lends.
Kiniksa heads into its third-quarter report with an unusual problem for a biotech: its own guidance may be more aggressive than the Street. After raising its 2026 revenue outlook for the second straight quarter, management now expects $980 million to $995 million in sales. Analysts' full-year consensus of roughly $939 million still sits below the bottom of that range. The question on October 27 is whether the quarter shows the recurrent pericarditis franchise accelerating fast enough to make the new range look comfortable rather than ambitious.
For American Assets Trust, the third-quarter report is less about the headline numbers than about a calendar. Management has spent three straight calls walking down its year-end office lease-rate target, and last quarter it described the timing of a few large deals as essentially binary. With only one quarter left in 2026 after this report, investors need to learn whether those deals are landing this year or sliding into 2027. The answer determines whether the company's embedded-earnings story is merely delayed or quietly losing credibility.
Arch Capital heads into its third-quarter report with a story that has quietly flipped. For years the pitch was disciplined growth into a hard market. Now the property and casualty franchise is shrinking, margins are leaking, and the most dynamic line on the income statement is share repurchases. When the company reports after the close on October 27, the question is whether mortgage insurance, investment income and an aggressive buyback can keep cushioning returns while management works through what it called the early stages of a competitive cycle.
Artisan Partners heads into its September-quarter report with a split personality. Its margins, investment performance and capital return have been improving, but the business suffered its worst flow quarter in recent memory as it shut down a U.S. Value franchise that had operated for roughly three decades. The stock has fallen about 23% since the last report while the S&P 500 rose about 3%. That tells you which half of the story the market chose to believe. This report is the first full quarter after the wind-down, and it should show whether the outflows were a one-time reset or the start of a longer slide.
Last quarter Banc of California deliberately took a large one-time loss, selling low-yielding securities, offloading troubled real estate loans and retiring expensive subordinated debt, all in the name of what management framed as the bank's true earnings power. The third-quarter report, due after the close on October 27, is the first chance to see whether that earnings power actually shows up. The market is skeptical: the shares have fallen 13.4% since the last report while the S&P 500 gained 3.2%.
BigBear.ai heads into its third-quarter report with a split personality. The top line finally started growing again last quarter, gross margins are sitting far above where they were a year ago, and management sounded more confident than it has in some time. Yet losses widened, cash kept shrinking, and the stock has lost nearly a quarter of its value since that report. The question for Tuesday's release, due after the close on October 27, is whether the operating momentum is real enough to justify the spending that is funding it.
For most of the past year, Beta Bionics gave investors a simple rhythm to follow: report a solid quarter, then lift the outlook. That rhythm broke last quarter. Management reaffirmed rather than raised its full-year targets, and an analyst pointed out that sequential growth in new patient starts had come in below the usual seasonal pattern. The third-quarter report, due after the close on October 27, is the first chance to learn whether that was a pause or the start of a slower chapter for the insulin pump maker.
Baker Hughes enters its third-quarter report with an unusual disconnect. Three months ago management delivered record orders, lifted guidance on almost every line and closed the Chart Industries deal, yet the stock has fallen 8.1% since then while the S&P 500 gained 2.5%. This report, the first to include Chart as a third reporting segment, is where the company has to show that its improving story turns into reported numbers rather than staying a backlog promise.
DMC Global heads into its third-quarter report with an unusual disconnect. Last quarter management delivered its most confident message in a year, beating its own profit range and guiding to further sequential gains in all three businesses. The stock has gone the other way, falling about 24% since that report while the S&P 500 rose nearly 4%. At $5.33, shares sit well below the 200-day moving average of $6.62 and just above the post-earnings low of $5.15. The market is treating the improvement as unproven, and this report is the chance to show it is real.
BrightSpire Capital heads into its third-quarter report with a split personality. Its lending engine is running faster than at any point in years, yet the stock has fallen almost 28% since the last report, trailing the S&P 500 by about 31 percentage points. The gap between those two stories, a growing loan book on one side and a shrinking book value and delayed dividend coverage on the other, is what the October 27 release has to resolve.
First Busey heads into its third-quarter report with a curious mismatch. The earnings bar is modest, and the shares still trade comfortably above their long-term trend. Yet sentiment toward the Urbana, Illinois lender has soured sharply since last quarter. That leaves the report less as a test of whether the bank can clear the consensus number and more as a test of whether it can calm a market that has quietly grown doubtful.
BXP heads into its third-quarter report with an unusual disconnect. Management raised full-year guidance for a second straight quarter in July, sounded more confident than at any point in the past year, and described a recovery shifting from filling empty space to pushing rents higher. The stock has gone the other way, falling 15.8% since that report while the S&P 500 gained 3.2%. The October 27 release, due after the close, needs to show whether the operating story still holds or whether the market has spotted something the guidance does not capture.
The Cheesecake Factory spent years being described as steady. Last quarter it became something more interesting: a casual-dining chain with accelerating traffic, a decade-high margin at its flagship brand and a rewards app that management credits with bringing in genuinely new guests. The stock has since rallied hard, so the third-quarter report due after the close on October 27 is less about whether the business is healthy and more about whether the second-quarter breakout was the start of a trend or a single standout period.
Chemed has spent 2026 turning a hospice crisis into a growth story, raising its full-year earnings outlook three times as VITAS shook off the Florida Medicare-cap problem that hobbled it last year. The stock has not followed along. Shares have slipped about 2% since the last report while the S&P 500 gained roughly 3%, which sets up a third-quarter release where the question is less whether the recovery is real and more whether it still has room to surprise.
Crane enters its third-quarter report with an unusual mismatch between what management has been saying and how the market has been behaving. Over six months the company lifted its full-year adjusted EPS outlook twice, reported a record operating margin and said its big acquisition was running well ahead of plan. Yet the stock has slipped 5.4% since the last report while the S&P 500 gained 3.2%, and sentiment has swung from solidly bullish to modestly bearish. This report needs to show that the confidence was earned, and the clearest test sits in the one business that has not yet turned: Process Flow Technologies.
CoStar Group heads into its third-quarter report on October 27 with a story that has quietly flipped. For years the pitch was revenue growth funded by heavy spending. Last quarter, management traded some of that growth for profit, cutting full-year revenue guidance for the first time in this cycle while holding firm on earnings. The stock has since rallied about 24%, so the market has clearly accepted the swap. This report will show whether the bargain is holding, or whether slower sales are starting to eat into the margin gains.
CTO Realty Growth heads into its third-quarter report with an awkward split between what management said and what the market has done. Three months ago the company raised its outlook on funds from operations, investment volume and same-property income all at once, cut leverage and sounded more confident than it has in a year. The stock has since fallen 7.4% while the S&P 500 gained 3.2%. Tuesday's after-the-close release will help show whether that selloff reflects skepticism about the story or just the slowdown management itself warned about.
Caesars Entertainment heads into its third-quarter report with an unusual setup. Wall Street expects revenue to be essentially unchanged from the prior quarter, yet it is counting on the bottom line to improve dramatically. That gap between a flat top line and a sharply narrower loss is the central question for the report, due after the close on October 27, and it puts the spotlight on cost discipline and below-the-line items rather than demand alone.
Enphase Energy enters its third-quarter report with a split personality. One side of the story is genuinely improving: gross margins have recovered, Europe is rebounding, Safe Harbor orders are piling up, and the product pipeline now reaches from GaN microinverters to transformers for AI data centers. The other side is a U.S. residential business that keeps shrinking. Since the last report, the market has sided firmly with the pessimists, and this quarter has to show that the core has stabilized rather than slid further.